Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cost-benefit rulings ahead at Germany's Gemeinsame Bundesausschuss:

This article was originally published in Clinica

Executive Summary

Germany's Gemeinsame Bundesausschuss (G-BA), the joint federal committee that decides whether healthcare products are reimbursable, used cost-benefit analysis for the first time this week in coming to a decision on genetically-engineered insulin analog. So reported FT Deutschland, of a decision that will resonate not just throughout the pharma sector, but will have implications for device manufacturers too. In declining reimbursement of the product for all but exceptional cases, the G-BA followed the 2004 recommendation of its executive arm, the IQWiG. Its decision effectively said that the benefits for type-2 diabetes sufferers do not match the euro30m ($38m) spent annually on the medication. It will now be used only when it is not more expensive than conventional human insulin (it is currently at a premium of 30-60%). There are 250,000 sufferers of type-2 diabetes in Germany. IQWiG will doubtless feel empowered by the public vindication of its decision; more evaluations (for asthma and high blood pressure, etc) lie ahead.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel